OBJECTIVE: To investigate the efficacy of a polyethylene glycol (PEG) modified formulation of liposome-encapsulated hemoglobin (LEH) as an oxygen-carrying blood substitute in the treatment of critical normovolemic anemia. DESIGN AND SETTING: Prospective, controlled, randomized experimental study in a university research facility. SUBJECTS: 14 anesthetized and mechanically ventilated beagle dogs. INTERVENTIONS: Animals were splenectomized and hemodiluted by exchange of whole blood for iso-oncotic hetastarch (HES). Target parameter of the hemodilution protocol was the individual critical hemoglobin concentration (Hb(crit)) corresponding with the onset of O(2) supply dependency of total body O(2) consumption. At Hb(crit) animals were randomized to receive a bolus infusion (20[Symbol: see text]ml/kg) of either LEH (n = 7) or normal saline (NS; n = 7). Subsequently animals were observed without further intervention. MEASUREMENTS AND RESULTS: The primary endpoint was survival time after the completion of treatment; secondary endpoints were parameters of central hemodynamics, O(2) transport and tissue oxygenation. Animals in the LEH group survived significantly longer after completion of treatment (149 +/- 109 vs. 43+/- 56 min). Immediately after treatment LEH-treated animals presented with a more stable cardiovascular condition. After 30 min tissue O(2) tension on the surface of a skeletal muscle was significantly higher in the LEH group (23+/-8 vs. 9 +/- 2 mmHg). Nevertheless, treatment with LEH did not decrease mortality within the observation period. CONCLUSIONS: In this present experimental study the infusion of a PEG-modified LEH provided adequate tissue oxygenation, hemodynamic stability, and a prolongation of survival time after critical anemia. However, these effects were sustained for only a short period of time.
OBJECTIVE: To investigate the efficacy of a polyethylene glycol (PEG) modified formulation of liposome-encapsulated hemoglobin (LEH) as an oxygen-carrying blood substitute in the treatment of critical normovolemic anemia. DESIGN AND SETTING: Prospective, controlled, randomized experimental study in a university research facility. SUBJECTS: 14 anesthetized and mechanically ventilated beagle dogs. INTERVENTIONS: Animals were splenectomized and hemodiluted by exchange of whole blood for iso-oncotic hetastarch (HES). Target parameter of the hemodilution protocol was the individual critical hemoglobin concentration (Hb(crit)) corresponding with the onset of O(2) supply dependency of total body O(2) consumption. At Hb(crit) animals were randomized to receive a bolus infusion (20[Symbol: see text]ml/kg) of either LEH (n = 7) or normal saline (NS; n = 7). Subsequently animals were observed without further intervention. MEASUREMENTS AND RESULTS: The primary endpoint was survival time after the completion of treatment; secondary endpoints were parameters of central hemodynamics, O(2) transport and tissue oxygenation. Animals in the LEH group survived significantly longer after completion of treatment (149 +/- 109 vs. 43+/- 56 min). Immediately after treatment LEH-treated animals presented with a more stable cardiovascular condition. After 30 min tissue O(2) tension on the surface of a skeletal muscle was significantly higher in the LEH group (23+/-8 vs. 9 +/- 2 mmHg). Nevertheless, treatment with LEH did not decrease mortality within the observation period. CONCLUSIONS: In this present experimental study the infusion of a PEG-modified LEH provided adequate tissue oxygenation, hemodynamic stability, and a prolongation of survival time after critical anemia. However, these effects were sustained for only a short period of time.
Authors: Timothy S Walsh; Robert J Lee; Caroline R Maciver; Magnus Garrioch; Fiona Mackirdy; Alexander R Binning; Stephen Cole; D Brian McClelland Journal: Intensive Care Med Date: 2005-11-23 Impact factor: 17.440
Authors: Santiago Ramón Leal-Noval; María Dolores Rincón-Ferrari; Ana Marin-Niebla; Aurelio Cayuela; Victoria Arellano-Orden; Antonio Marín-Caballos; Rosario Amaya-Villar; Carmen Ferrándiz-Millón; Francisco Murillo-Cabeza Journal: Intensive Care Med Date: 2006-09-22 Impact factor: 17.440
Authors: Jens Meier; Andreas Pape; Daria Loniewska; Patrick Lauscher; Harry Kertscho; Bernhard Zwissler; Oliver Habler Journal: Crit Care Med Date: 2007-06 Impact factor: 7.598
Authors: Andreas Pape; Saskia Kutschker; Harry Kertscho; Peter Stein; Oliver Horn; Mischa Lossen; Bernhard Zwissler; Oliver Habler Journal: Crit Care Date: 2012-12-12 Impact factor: 9.097
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2009-01-06 Impact factor: 17.440